- 23andMe Holding Co. is the leading direct-to-consumer genetic testing company entering drug development with data on 11.3M Genotyped Customers and +$696M in SPAC funding.
- 23andMe's core products include a suite of D2C genetic reports covering ancestry, genetic health risks, carrier status, and medication responses and 40+ programs (2 clinical-stage) for therapeutic development.
- 23andMe's lead therapeutic program is GSK'608, an anti-CD96 immuno-oncology therapeutic developed under the GSK collaboration with 23andMe's data which included a $300M equity component.
- 23andMe Holding Co. is in a strong financial position with TTM revenues of $244M and management guidance outlining revenues reaching $400M by 2024 with an expected 18% CAGR.
- In summary, the author projects 23andMe Holding Co. as a strong "buy" at a 2-3 year price target of $14.3/share (+44% upside).
For further details see:
23andMe: New Therapeutic Pipeline And PGS Product Growth Catalyzed By +$696M In SPAC Funding